Comparative Pharmacology
Head-to-head clinical analysis: AIRSUPRA versus BECLOVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRSUPRA versus BECLOVENT.
AIRSUPRA vs BECLOVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIRSUPRA is a fixed-dose combination of albuterol (a short-acting beta2-agonist) and budesonide (an inhaled corticosteroid). Albuterol relaxes bronchial smooth muscle via beta2-adrenergic receptor activation, increasing cAMP and causing bronchodilation. Budesonide reduces airway inflammation by binding to glucocorticoid receptors, modulating gene transcription to suppress inflammatory mediators.
Glucocorticoid receptor agonist; inhibits inflammatory mediators, reduces airway hyperresponsiveness, and suppresses immune cell activity.
2 inhalations (albuterol 180 mcg / budesonide 160 mcg) orally inhaled twice daily (morning and evening), maximum 2 inhalations twice daily.
2 inhalations (84 mcg) twice daily; not to exceed 10 inhalations (420 mcg) per day. Administered via oral inhalation using a metered-dose inhaler.
None Documented
None Documented
Budesonide: 2-3 hours; formoterol: 10-14 hours; clinical context: steady state achieved within days for both
Terminal elimination half-life of beclomethasone dipropionate is 0.5 hours; active metabolite beclomethasone-17-monopropionate has half-life of 2.7 hours; clinically, systemic effects persist for 12-24 hours.
Budesonide: ~60% renal as metabolites, ~40% fecal; formoterol: ~60% renal, ~40% fecal
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (60-70%) and urine (10-15%); less than 5% unchanged drug in urine.
Category C
Category C
Inhaled Corticosteroid/SABA Combination
Inhaled Corticosteroid